[Glecaprevir/pibrentasvir in combination with ribavirin as salvage therapy in chronic hepatitis C].
作者信息
Sánchez Suárez M M, Martín Roldán A, Cantudo Cuenca M R
机构信息
Alicia Martín Roldán, Hospital Universitario Virgen de las Nieves. Postal address: Avenida de las Fuerzas Armadas, 2, 18014, Granada, Spain.
出版信息
Rev Esp Quimioter. 2024 Jun;37(3):283-284. doi: 10.37201/req/020.2024. Epub 2024 Apr 19.
Abstract
摘要
相似文献
1
[Glecaprevir/pibrentasvir in combination with ribavirin as salvage therapy in chronic hepatitis C].
Rev Esp Quimioter. 2024 Jun;37(3):283-284. doi: 10.37201/req/020.2024. Epub 2024 Apr 19.
2
Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance.
Clin Microbiol Infect. 2020 Sep;26(9):1266-1268. doi: 10.1016/j.cmi.2020.03.022. Epub 2020 Mar 30.
3
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.
Adv Ther. 2020 Sep;37(9):4033-4042. doi: 10.1007/s12325-020-01449-0. Epub 2020 Aug 4.
4
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
J Viral Hepat. 2020 Jun;27(6):568-575. doi: 10.1111/jvh.13265. Epub 2020 Feb 6.
5
Glecaprevir/pibrentasvir ultra-short treatment to cure HCV infection: case report and literature review.
Infez Med. 2020 Dec 1;28(4):616-620.
6
Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
Viruses. 2018 Aug 28;10(9):462. doi: 10.3390/v10090462.
7
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan.
Sci Rep. 2021 Dec 6;11(1):23473. doi: 10.1038/s41598-021-03006-3.
8
Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
J Am Soc Nephrol. 2020 Nov;31(11):2678-2687. doi: 10.1681/ASN.2020050686. Epub 2020 Aug 25.
9
Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.
Hepatology. 2021 Oct;74(4):2304-2306. doi: 10.1002/hep.31909. Epub 2021 Jun 16.
10
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Hepatology. 2017 Aug;66(2):389-397. doi: 10.1002/hep.29081. Epub 2017 Apr 10.
本文引用的文献
1
Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
Clin Infect Dis. 2023 May 25. doi: 10.1093/cid/ciad319.
2
Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.
Hepatology. 2021 Oct;74(4):2304-2306. doi: 10.1002/hep.31909. Epub 2021 Jun 16.
3
Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings.
J Hepatol. 2021 Jul;75(1):251-254. doi: 10.1016/j.jhep.2021.02.024. Epub 2021 Feb 27.
4
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
J Hepatol. 2021 Apr;74(4):801-810. doi: 10.1016/j.jhep.2020.11.017. Epub 2020 Nov 19.
5
Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report.
Z Gastroenterol. 2020 May;58(5):451-455. doi: 10.1055/a-1131-8058. Epub 2020 May 11.
6
Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance.
Clin Microbiol Infect. 2020 Sep;26(9):1266-1268. doi: 10.1016/j.cmi.2020.03.022. Epub 2020 Mar 30.
7
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.
J Hepatol. 2019 May;70(5):1019-1023. doi: 10.1016/j.jhep.2019.01.031. Epub 2019 Mar 8.
Zotero 插件